Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease

被引:44
作者
Kitson, Matthew T. [1 ]
Kemp, William W. [1 ]
Iser, David M. [2 ]
Paul, Eldho [3 ]
Wilson, John W. [4 ]
Roberts, Stuart K. [1 ]
机构
[1] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[2] Alfred Hosp, Infect Dis Unit, Melbourne, Vic, Australia
[3] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia
[4] Alfred Hosp, Dept Allergy Immunol & Resp Med, Cyst Fibrosis Serv, Melbourne, Vic, Australia
关键词
cystic fibrosis; liver fibrosis; liver stiffness measurement; portal hypertension; transient elastography; PORTAL-HYPERTENSION; HEPATIC-FIBROSIS; CIRRHOSIS; PERFORMANCE; MANAGEMENT; FIBROTEST; DIAGNOSIS; STIFFNESS; BIOPSY; INDEX;
D O I
10.1111/liv.12113
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Liver disease frequently complicates cystic fibrosis (CF), with CF liver disease (CFLD) a leading cause of death. Liver biopsy is rarely performed because of the patchy nature of the disease. Transient elastography can reliably stage liver fibrosis via liver stiffness measurement (LSM). Aims To evaluate LSM as a diagnostic tool in adults with CFLD. Methods Fifty adult patients with CF were prospectively studied: 25 with CFLD and 25 without CFLD. The presence of CFLD and portal hypertension (PHT) was assessed according to strict established criteria based on serial biochemistry and imaging. All patients underwent LSM; APRI, Hepascore (R) and Forns score were calculated. Results Median LSM was higher in those with CFLD [8.1 kPa (IQR 6.89.5) vs. 5.0 kPa (IQR 4.15.6); P<0.001]. On multivariate analysis, LSM was the only variable associated with CFLD (OR 2.74, 95% CI 1.534.89; P=0.001). AUROC for LSM predicting CFLD was 0.87 (95% CI 0.770.98) and an LSM 6.8 kPa predicted CFLD with 76.0% sensitivity and 92.0% specificity. Median LSM was higher in those with PHT [15.7 kPa (IQR 9.217.2) vs. 5.4 kPa (IQR 4.36.8); P<0.001]. The AUROC for LSM predicting the presence of PHT was 0.96 (95% CI 0.921.00). An LSM cut-off of 8.9 kPa predicted the presence of PHT with 87.5% sensitivity, 90.5% specificity, 63.6% positive predictive value and 92.9% negative predictive value. Conclusions LSM is an accurate and reliable non-invasive tool in assessing CFLD and PHT. An LSM 6.8 kPa is highly suggestive of CFLD and an LSM <8.9 kPa reliably excludes PHT.
引用
收藏
页码:698 / 705
页数:8
相关论文
共 30 条
  • [1] Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection
    Adams, LA
    Bulsara, M
    Rossi, E
    Deboer, B
    Speers, D
    George, J
    Kench, J
    Farrell, G
    McCaughan, GW
    Jeffrey, GP
    [J]. CLINICAL CHEMISTRY, 2005, 51 (10) : 1867 - 1873
  • [2] A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease
    Casey, Stephen P.
    Kemp, William W.
    McLean, Catriona A.
    Topliss, Duncan J.
    Adams, Leon A.
    Roberts, Stuart K.
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2012, 47 (07) : 836 - 841
  • [3] Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
    Castéra, L
    Vergniol, J
    Foucher, J
    Le Bail, B
    Chanteloup, E
    Haaser, M
    Darriet, M
    Couzigou, P
    De Lédinghen, V
    [J]. GASTROENTEROLOGY, 2005, 128 (02) : 343 - 350
  • [4] LOCALIZATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN HUMAN BILE-DUCT EPITHELIAL-CELLS
    COHN, JA
    STRONG, TV
    PICCIOTTO, MR
    NAIRN, AC
    COLLINS, FS
    FITZ, JG
    [J]. GASTROENTEROLOGY, 1993, 105 (06) : 1857 - 1864
  • [5] Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome
    Colombo, C
    Battezzati, PM
    Crosignani, A
    Morabito, A
    Costantini, D
    Padoan, R
    Giunta, A
    [J]. HEPATOLOGY, 2002, 36 (06) : 1374 - 1382
  • [6] SCINTIGRAPHIC DOCUMENTATION OF AN IMPROVEMENT IN HEPATOBILIARY EXCRETORY FUNCTION AFTER TREATMENT WITH URSODEOXYCHOLIC ACID IN PATIENTS WITH CYSTIC-FIBROSIS AND ASSOCIATED LIVER-DISEASE
    COLOMBO, C
    CASTELLANI, MR
    BALISTRERI, WF
    SEREGNI, E
    ASSAISSO, ML
    GIUNTA, A
    [J]. HEPATOLOGY, 1992, 15 (04) : 677 - 684
  • [7] Liver disease in cystic fibrosis
    Colombo, Carla
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2007, 13 (06) : 529 - 536
  • [8] Liver disease in cystic fibrosis
    Colombo, Carla
    Russo, Maria Chiara
    Zazzeron, Laura
    Romano, Giovanna
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2006, 43 : S49 - S55
  • [9] Liver stiffness measurement in children using FibroScan:: Feasibility study and comparison with fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy
    de Ledinghen, Victor
    Le Bail, Brigitte
    Rebouissoux, Laurent
    Fournier, Celine
    Foucher, Juliette
    Miette, Veronique
    Castera, Laurent
    Sandrin, Laurent
    Merrouche, Wassil
    Lavrand, Frederic
    Lamireau, Thierry
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2007, 45 (04) : 443 - 450
  • [10] Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension
    Debray, D
    Lykavieris, P
    Gauthier, F
    Dousset, B
    Sardet, A
    Munck, A
    Laselve, H
    Bernard, O
    [J]. JOURNAL OF HEPATOLOGY, 1999, 31 (01) : 77 - 83